Get the Stockscreener App
14.12
0.98%
-0.14
After Hours:
14.26
0.14
+0.99%
Amylyx Pharmaceuticals Inc stock is traded at $14.12, with a volume of 1.62M.
It is down -0.98% in the last 24 hours and up +21.20% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$14.26
Open:
$14.24
24h Volume:
1.62M
Relative Volume:
1.00
Market Cap:
$1.26B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-5.648
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
+11.27%
1M Performance:
+21.20%
6M Performance:
+286.85%
1Y Performance:
+297.75%
1-Day Range:
$13.92
$14.30
1-Week Range:
$12.39
$15.16
52-Week Range:
$2.865
$15.16
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.12 | 1.52B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals, Inc. Securities Lawsuit Investigation - Claim Depot
Using economic indicators to assess Amylyx Pharmaceuticals Inc. potentialQuarterly Market Summary & Weekly Chart Analysis and Trade Guides - newser.com
Why Amylyx Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, - GlobeNewswire
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidance2025 Volatility Report & Smart Allocation Stock Tips - newser.com
Using flow based indicators on Amylyx Pharmaceuticals Inc.Day Trade & Fast Momentum Entry Tips - newser.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9.6%Should You Buy? - MarketBeat
Key metrics from Amylyx Pharmaceuticals Inc.’s quarterly dataWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Will Amylyx Pharmaceuticals Inc. continue its uptrendJuly 2025 Trends & Safe Capital Growth Plans - newser.com
Best data tools to analyze Amylyx Pharmaceuticals Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Leerink Partnrs Has Bullish Forecast for AMLX Q3 Earnings - MarketBeat
How supply chain issues affect Amylyx Pharmaceuticals Inc. stockBond Market & Accurate Buy Signal Alerts - newser.com
Could Legal Scrutiny of AMLX’s Disclosures Reshape Management Credibility at Amylyx Pharmaceuticals? - simplywall.st
Institutional scanner results for Amylyx Pharmaceuticals Inc.Weekly Stock Report & High Yield Stock Recommendations - newser.com
Will Amylyx Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Setup with High ROI Potential - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
MarketsMedicine Hat News - FinancialContent
Amylyx Faced With Big Rally Reality Check: Why I Choose To Hold (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4%What's Next? - MarketBeat
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - cnhinews.com
Amylyx Pharmaceuticals prices $175M public offering - MSN
Visual analytics tools that track Amylyx Pharmaceuticals Inc. performanceQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - Nasdaq
Amylyx drops clinical program for neuro disorder after trial readout - MSN
Amylyx Will Battle Investor Suit Over Revoked ALS Treatment (1) - Bloomberg Law News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Amylyx stock price target raised to $16 from $14 at BofA Securities - Investing.com
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $16 - 富途牛牛
Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target - TipRanks
Amylyx Pharmaceuticals Executives Cash In on Major Stock Sales! - TipRanks
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $128,712.24 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Camille Bedrosian Sells 12,039 Shares - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO Sells $154,674.70 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Justin Klee Sells 29,975 Shares - MarketBeat
Amylyx Pharmaceuticals Inc Stock Analysis and ForecastVolume Spike Alerts & Free Trading Psychology Sessions - earlytimes.in
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Down 6.5%Here's What Happened - MarketBeat
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Amylyx Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighWhat's Next? - MarketBeat
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Sep 30 '25 |
Sale |
14.58 |
8,828 |
128,669 |
148,141 |
| FRATES JAMES M | Chief Financial Officer |
Sep 30 '25 |
Sale |
14.65 |
10,558 |
154,650 |
280,430 |
| Cohen Joshua B | Co-Chief Executive Officer |
Sep 30 '25 |
Sale |
14.35 |
29,933 |
429,469 |
3,325,347 |
| Bedrosian Camille L | Chief Medical Officer |
Sep 30 '25 |
Sale |
14.58 |
12,039 |
175,518 |
182,336 |
| Mazzariello Gina | Chief Legal Officer |
Aug 13 '25 |
Sale |
8.34 |
15,000 |
125,046 |
156,969 |
| Mazzariello Gina | Chief Legal Officer |
Aug 12 '25 |
Sale |
8.07 |
15,000 |
121,102 |
171,969 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):